Company / Shareholders' Equity
Century Therapeutics, Inc. Shareholders' Equity History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$161.4M
FY2025
5-year range
$161.4M / $396.2M
FY2022-FY2025
Trend
-12.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $396M in FY2022 to $161M in FY2025.
Based on SEC 10-K filings.
$161M in FY2025 with a 3-year CAGR of -25.9%.
Declined from $303M to $161M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -25.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Century Therapeutics, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 3-year CAGR of -25.9%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 12.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $161.4M | -12.7% |
| FY2024 | $184.8M | -39.0% |
| FY2023 | $302.7M | -23.6% |
| FY2022 | $396.2M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026